{"title":"CGRP promotes osteogenic differentiation by regulating macrophage M2 polarization through HDAC6/AKAP12 signaling pathway.","authors":"Wenjing Chen, Lin Ma, Wencai Sun, Wenlong Xiao, Hao Guo, Jiang Xiu, Xin Jiang","doi":"10.1080/17460751.2024.2370697","DOIUrl":"10.1080/17460751.2024.2370697","url":null,"abstract":"<p><p><b>Aim:</b> To determine the mechanism of Calcitonin gene-related peptide (CGRP) in bone healing.<b>Materials & methods:</b> Alkaline phosphatase (ALP) activity and inflammatory-factor levels were detected using ELISA. Osteogenic differentiation was assessed using Alizarin red staining technique. The interaction between histone deacetylase 6 (HDAC6) and A-kinase anchoring protein 12 (AKAP12) was investigated through Co- immunoprecipitation.<b>Results:</b> CGRP treatment promoted rat bone marrow-derived macrophages (BMDMs) M2 polarization. CGRP facilitated osteogenic differentiation by enhancing M2 polarization of BMDMs. Mechanistically, CGRP promoted AKAP12 acetylation to activate the extracellular regulated protein kinases pathway by HDAC6 inhibition.<b>Conclusion:</b> CGRP promoted M2 polarization of rat BMDMs and facilitated osteogenic differentiation through the HDAC6/AKAP12/extracellular regulated protein kinases signaling pathway, thereby promoting bone healing.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"379-391"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-06-28DOI: 10.1080/17460751.2024.2365027
Dusko Ilic, Mirjana Liovic
{"title":"Industry updates from the field of stem cell research and regenerative medicine in April 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2365027","DOIUrl":"10.1080/17460751.2024.2365027","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in April 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"365-374"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-05-28DOI: 10.1080/17460751.2024.2353496
Dusko Ilic, Mirjana Liovic
{"title":"Industry updates from the field of stem cell research and regenerative medicine in March 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2353496","DOIUrl":"10.1080/17460751.2024.2353496","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in March 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"19 7-8","pages":"355-363"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-09-02DOI: 10.1080/17460751.2024.2386214
Manon van Daal, Anne-Floor J de Kanter, Roel Jh Custers, Elena Martínez-Sanz, Annelien L Bredenoord, Nienke de Graeff
{"title":"Patient, parent and professional expert perspectives on personalized regenerative implants: a qualitative focus group study.","authors":"Manon van Daal, Anne-Floor J de Kanter, Roel Jh Custers, Elena Martínez-Sanz, Annelien L Bredenoord, Nienke de Graeff","doi":"10.1080/17460751.2024.2386214","DOIUrl":"10.1080/17460751.2024.2386214","url":null,"abstract":"<p><p><b>Background:</b> Perspectives of patients, parents and professional experts on personalized regenerative implants for regenerative medicine purposes are largely unknown.<b>Method:</b> To better understand these perspectives, we conducted four focus groups with professional experts of mixed European nationality (n = 8), Dutch patients with regular implants (n = 8), Dutch and Belgian (n = 5) and Spanish (n = 8) parents of children with cleft palate.<b>Results:</b> Two overarching themes were identified: 'patient-centered research and care' and 'ambivalent attitudes toward personalized regenerative implants'.<b>Discussion:</b> The results reveal that stakeholders should adopt a participatory rather than an impairment discourse and address the ambivalence among professional experts, patients and parents.<b>Conclusion:</b> Considering stakeholder perspectives facilitates ethical and responsible development and use of personalized regenerative implants.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"19 7-8","pages":"393-406"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-01-19DOI: 10.2217/rme-2023-0187
Aldyn Wildey, Stephen Harrington, Lisa Stehno-Bittel, Francis Karanu
{"title":"Reduction of Activin A gives rise to comparable expression of key definitive endoderm and mature beta cell markers.","authors":"Aldyn Wildey, Stephen Harrington, Lisa Stehno-Bittel, Francis Karanu","doi":"10.2217/rme-2023-0187","DOIUrl":"10.2217/rme-2023-0187","url":null,"abstract":"<p><p><b>Aim:</b> Cell therapies for diabetes rely on differentiation of stem cells into insulin-producing cells, which is complex and expensive. Our goal was to evaluate production costs and test ways to reduce it. <b>Methods:</b> Cost of Goods (COGs) analysis for differentiation was completed and the effects of replacement or reduction of the most expensive item was tested using qRT-PCR, immunohistochemistry, flow cytometry along with glucose-stimulated insulin release. <b>Results:</b> Activin A (AA) was responsible for significant cost. Replacement with small molecules failed to form definitive endoderm (DE). Reducing AA by 50% did not negatively affect expression of beta cell markers. <b>Conclusion:</b> Reduction of AA concentration is feasible without adversely affecting DE and islet-like cell differentiation, leading to significant cost savings in manufacturing.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"47-63"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-02-08DOI: 10.2217/rme-2023-0110
James E Wilson, Bobbie A Today, Maria Salazar, Jonathann Kuo, John T Ransom, Amy L Lightner, Grace Chen, Anita Wong
{"title":"Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain.","authors":"James E Wilson, Bobbie A Today, Maria Salazar, Jonathann Kuo, John T Ransom, Amy L Lightner, Grace Chen, Anita Wong","doi":"10.2217/rme-2023-0110","DOIUrl":"10.2217/rme-2023-0110","url":null,"abstract":"<p><p><b>Aim:</b> A 3-month pilot study to evaluate the safety of injecting a bone marrow-derived mesenchymal stem cell extracellular vesicle advanced investigational product (IP) into the lumbar facet joint space as a treatment for chronic low back pain. <b>Methods:</b> 20 healthy adults were treated with IP injections (0.5 ml/joint) and evaluated by three functional assessments 1, 3, 7, 14, 30, 60 and 90 days later. <b>Results:</b> No adverse effects or complications occurred across the 3-month follow-up. There were no reports of worsening pain. After 3 months group average scores improved significantly (p < 0.0001) in the Severity Index (65.04%), Interference Index (72.09%) and Oswestry Disability Index (58.43%) assessments. <b>Conclusion:</b> IP injections were safe and associated with significant functional improvements.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"19-26"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-08-05DOI: 10.1080/17460751.2024.2378615
Sanyam Jain, Jai Gopal Sharma
{"title":"Unconventional strategies for liver tissue engineering: plant, paper, silk and nanomaterial-based scaffolds.","authors":"Sanyam Jain, Jai Gopal Sharma","doi":"10.1080/17460751.2024.2378615","DOIUrl":"10.1080/17460751.2024.2378615","url":null,"abstract":"<p><p>The paper highlights how significant characteristics of liver can be modeled in tissue-engineered constructs using unconventional scaffolds. Hepatic lobular organization and metabolic zonation can be mimicked with decellularized plant structures with vasculature resembling a native-hepatic lobule vascular arrangement or silk blend scaffolds meticulously designed for guided cellular arrangement as hepatic patches or metabolic activities. The functionality of hepatocytes can be enhanced and maintained for long periods in naturally fibrous structures paving way for bioartificial liver development. The phase I enzymatic activity in hepatic models can be raised exploiting the microfibrillar structure of paper to allow cellular stacking creating hypoxic conditions to induce <i>in vivo</i>-like xenobiotic metabolism. Lastly, the paper introduces amalgamation of carbon-based nanomaterials into existing scaffolds in liver tissue engineering.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"421-437"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-07-26DOI: 10.1080/17460751.2024.2378627
Madhurima Das, Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale
{"title":"Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management.","authors":"Madhurima Das, Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale","doi":"10.1080/17460751.2024.2378627","DOIUrl":"10.1080/17460751.2024.2378627","url":null,"abstract":"<p><p>CD45 plays a crucial role in the regulation of hematopoiesis. However, a comprehensive understanding of its role in <i>non-hematopoietic</i> cells is lacking. Several tissue precursors express CD45, indicating its crucial role in tissue regeneration. These precursors would fall prey to the recent therapies involving CD45 as a target. CD45<sup>+</sup> double-positive tumor cells contribute to cancer progression, but whether CD45 is involved in the process needs to be investigated. Recently, we showed that aging induces CD45 expression in mesenchymal stromal cells and affects their differentiation potential. In this review, we, for the first time, unravel the important implications of the expression of CD45 in <i>non-hematopoietic</i> cells and provide novel insights into its potential therapeutic target in regenerative medicine and disease management.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"407-419"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-07-16DOI: 10.1080/17460751.2024.2368352
Isabella Devine, Clarice O'Brien, David Mockler, Cormac Kennedy, Gerry Hughes, Martina Hennessy
{"title":"Exploring the readiness of the Irish healthcare system to adopt advanced therapies: a scoping review protocol.","authors":"Isabella Devine, Clarice O'Brien, David Mockler, Cormac Kennedy, Gerry Hughes, Martina Hennessy","doi":"10.1080/17460751.2024.2368352","DOIUrl":"10.1080/17460751.2024.2368352","url":null,"abstract":"<p><p><b>Aim:</b> Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. <b>Materials & methods:</b> Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted.<b>Results:</b> Findings will be presented via narrative summary, graphical and tabular formats.<b>Discussion:</b> Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"439-444"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regenerative medicinePub Date : 2024-01-01Epub Date: 2024-07-18DOI: 10.1080/17460751.2024.2375104
Darius Widera
{"title":"Exploring stem cell therapies: an interview with Darius Widera.","authors":"Darius Widera","doi":"10.1080/17460751.2024.2375104","DOIUrl":"10.1080/17460751.2024.2375104","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"375-377"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}